{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:22:29Z","timestamp":1750220549199,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":29,"publisher":"ACM","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,6]]},"DOI":"10.1145\/3444884.3444919","type":"proceedings-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T19:08:06Z","timestamp":1617217686000},"page":"180-183","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of Cancer Immunotherapy"],"prefix":"10.1145","author":[{"given":"Zihan","family":"Wang","sequence":"first","affiliation":[{"name":"Shenyang Pharmaceutical University, China"}]}],"member":"320","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"e_1_3_2_1_1_1","first-page":"7","volume":"202","author":"Siegel R.L.","unstructured":"Siegel , R.L. , K.D. Miller , and A. Jemal , Cancer statistics, 202 0. CA Cancer J Clin , 202 0. 70(1): p. 7 - 30 . Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_2_1_2_1","first-page":"61","volume":"201","author":"Wilkins O.","unstructured":"Wilkins , O. , A.M. Keeler , and T.R. Flotte , CAR T-Cell Therapy: Progress and Prospects. Human Gene Therapy Methods , 201 7. 28(2): p. 61 - 66 . Wilkins, O., A.M. Keeler, and T.R. Flotte, CAR T-Cell Therapy: Progress and Prospects. Human Gene Therapy Methods, 2017. 28(2): p. 61-66.","journal-title":"Prospects. Human Gene Therapy Methods"},{"key":"e_1_3_2_1_3_1","first-page":"342","volume":"201","author":"Pettitt D.","unstructured":"Pettitt , D. , , CAR- T Cells : A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape. Molecular Therapy , 201 8. 26(2): p. 342 - 353 . Pettitt, D., , CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape. Molecular Therapy, 2018. 26(2): p. 342-353.","journal-title":"Clinical Trial Landscape. Molecular Therapy"},{"key":"e_1_3_2_1_4_1","first-page":"499","volume":"201","author":"van der Stegen S.J.C.","unstructured":"van der Stegen , S.J.C. , M. Hamieh , and M. Sadelain , The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery , 201 5. 14(7): p. 499 - 509 . van der Stegen, S.J.C., M. Hamieh, and M. Sadelain, The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery, 2015. 14(7): p. 499-509.","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_3_2_1_5_1","first-page":"3112","volume":"201","author":"Wang Z.","unstructured":"Wang , Z. , , A long way to the battlefront: CAR T cell therapy against solid cancers. J Cancer , 201 9. 10(14): p. 3112 - 3123 . Wang, Z., , A long way to the battlefront: CAR T cell therapy against solid cancers. J Cancer, 2019. 10(14): p. 3112-3123.","journal-title":"J Cancer"},{"key":"e_1_3_2_1_6_1","first-page":"434","volume":"201","author":"Sun C.","unstructured":"Sun , C. , R. Mezzadra , and T.N. Schumacher , Regulation and Function of the PD-L1 Checkpoint. Immunity , 201 8. 48(3): p. 434 - 452 . Sun, C., R. Mezzadra, and T.N. Schumacher, Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018. 48(3): p. 434-452.","journal-title":"Checkpoint. Immunity"},{"key":"e_1_3_2_1_7_1","first-page":"571","volume":"201","author":"Morrison C.","unstructured":"Morrison , C. , CAR-T field booms as next-generation platforms attract big players. Nat Biotechnol , 201 5. 33(6): p. 571 - 572 . Morrison, C., CAR-T field booms as next-generation platforms attract big players. Nat Biotechnol, 2015. 33(6): p. 571-2.","journal-title":"Nat Biotechnol"},{"key":"e_1_3_2_1_8_1","first-page":"651","volume":"201","author":"Sakoda Y.","unstructured":"Sakoda , Y. and K. Tamada , [Development of cancer immunotherapy by next generation multi-targeting CAR-T cells]. Rinsho Ketsueki , 201 4. 55(6): p. 651 - 656 . Sakoda, Y. and K. Tamada, [Development of cancer immunotherapy by next generation multi-targeting CAR-T cells]. Rinsho Ketsueki, 2014. 55(6): p. 651-6.","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_2_1_9_1","first-page":"15","volume":"201","author":"Subklewe M.","unstructured":"Subklewe , M. , M. von Bergwelt-Baildon , and A. Humpe , Chimeric Antigen Receptor T Cells : A Race to Revolutionize Cancer Therapy. Transfus Med Hemother , 201 9. 46(1): p. 15 - 24 . Subklewe, M., M. von Bergwelt-Baildon, and A. Humpe, Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfus Med Hemother, 2019. 46(1): p. 15-24.","journal-title":"Revolutionize Cancer Therapy. Transfus Med Hemother"},{"key":"e_1_3_2_1_10_1","first-page":"61","volume":"201","author":"Wilkins O.","unstructured":"Wilkins , O. , A.M. Keeler , and T.R. Flotte , CAR T-Cell Therapy: Progress and Prospects. Hum Gene Ther Methods , 201 7. 28(2): p. 61 - 66 . Wilkins, O., A.M. Keeler, and T.R. Flotte, CAR T-Cell Therapy: Progress and Prospects. Hum Gene Ther Methods, 2017. 28(2): p. 61-66.","journal-title":"Prospects. Hum Gene Ther Methods"},{"key":"e_1_3_2_1_11_1","first-page":"e186","volume-title":"Hemasphere","author":"Yanez L.","year":"2019","unstructured":"Yanez , L. , M. Sanchez-Escamilla , and M.A. Perales , CAR T Cell Toxicity: Current Management and Future Directions . Hemasphere , 2019 . 3(2): p. e186 . Yanez, L., M. Sanchez-Escamilla, and M.A. Perales, CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere, 2019. 3(2): p. e186."},{"key":"e_1_3_2_1_12_1","volume":"201","author":"Combination","unstructured":"otte, A., Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res , 201 9. 38(1): p. 255. otte, A., Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res, 2019. 38(1): p. 255.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_2_1_13_1","first-page":"1","volume":"201","author":"Darvin P.","unstructured":"Darvin , P. , , Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med , 201 8. 50(12): p. 1 - 11 . Darvin, P., , Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med, 2018. 50(12): p. 1-11.","journal-title":"Exp Mol Med"},{"key":"e_1_3_2_1_14_1","first-page":"45","volume":"201","author":"Andrieu G.P.","unstructured":"Andrieu , G.P. , , BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Lett , 201 9. 465: p. 45 - 58 . Andrieu, G.P., , BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Lett, 2019. 465: p. 45-58.","journal-title":"Cancer Lett"},{"key":"e_1_3_2_1_15_1","first-page":"294","volume":"201","author":"Schutz F.","unstructured":"Schutz , F. , , PD-1\/PD-L1 Pathway in Breast Cancer. Oncol Res Treat , 201 7. 40(5): p. 294 - 297 . Schutz, F., , PD-1\/PD-L1 Pathway in Breast Cancer. Oncol Res Treat, 2017. 40(5): p. 294-297.","journal-title":"Breast Cancer. Oncol Res Treat"},{"key":"e_1_3_2_1_16_1","first-page":"3459","volume":"201","author":"Krummel M.F.","unstructured":"Krummel , M.F. and J.P. Allison , CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation. Journal of Immunology , 201 1. 187(7): p. 3459 - 3465 . Krummel, M.F. and J.P. Allison, CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation. Journal of Immunology, 2011. 187(7): p. 3459-3465.","journal-title":"Immunology"},{"key":"e_1_3_2_1_17_1","first-page":"405","volume":"201","author":"Curran K.J.","unstructured":"Curran , K.J. , H.J. Pegram , and R.J. Brentjens , Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med , 201 2. 14(6): p. 405 - 415 . Curran, K.J., H.J. Pegram, and R.J. Brentjens, Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med, 2012. 14(6): p. 405-15.","journal-title":"J Gene Med"},{"key":"e_1_3_2_1_18_1","volume":"201","author":"Liu D.","unstructured":"Liu , D. , J. Zhao , and Y. Song , Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol , 201 9. 12(1): p. 69. Liu, D., J. Zhao, and Y. Song, Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol, 2019. 12(1): p. 69.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_2_1_19_1","first-page":"1339","volume":"201","author":"Haji-Fatahaliha M.","unstructured":"Haji-Fatahaliha , M. , , CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol , 201 6. 44(6): p. 1339 - 1349 . Haji-Fatahaliha, M., , CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol, 2016. 44(6): p. 1339-49.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"e_1_3_2_1_20_1","first-page":"106","volume":"201","author":"Han Y.","unstructured":"Han , Y. , , Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res , 201 8. 8(1): p. 106 - 119 . Han, Y., , Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res, 2018. 8(1): p. 106-119.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_2_1_21_1","first-page":"409","volume":"201","author":"Jiang H.","unstructured":"Jiang , H. , , Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst , 201 9. 111(4): p. 409 - 418 . Jiang, H., , Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst, 2019. 111(4): p. 409-418.","journal-title":"Gastric Cancer. J Natl Cancer Inst"},{"key":"e_1_3_2_1_22_1","first-page":"e0198347","volume-title":"PLoS One","author":"Kim M.","year":"2018","unstructured":"Kim , M. , , Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer . PLoS One , 2018 . 13(6): p. e0198347 . Kim, M., , Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One, 2018. 13(6): p. e0198347."},{"key":"e_1_3_2_1_23_1","first-page":"478","volume":"201","author":"Liu H.","unstructured":"Liu , H. , , Targeting Alpha-Fetoprotein (AFP)- MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res , 201 7. 23(2): p. 478 - 488 . Liu, H., , Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res, 2017. 23(2): p. 478-488.","journal-title":"Liver Cancer. Clin Cancer Res"},{"key":"e_1_3_2_1_24_1","first-page":"687","volume":"201","author":"Neill T.","unstructured":"Neill , T. , , EphA2 is a functional receptor for the growth factor progranulin. Journal of Cell Biology , 201 6. 215(5): p. 687 - 703 . Neill, T., , EphA2 is a functional receptor for the growth factor progranulin. Journal of Cell Biology, 2016. 215(5): p. 687-703.","journal-title":"Cell Biology"},{"key":"e_1_3_2_1_25_1","volume-title":"CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel)","author":"Golubovskaya V.","year":"2017","unstructured":"Golubovskaya , V. , , CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel) , 2017 . 9(10). Golubovskaya, V., , CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel), 2017. 9(10)."},{"key":"e_1_3_2_1_26_1","first-page":"1637","volume":"201","author":"Kenderian S.S.","unstructured":"Kenderian , S.S. , , CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia , 201 5. 29(8): p. 1637 - 1647 . Kenderian, S.S., , CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 2015. 29(8): p. 1637-47.","journal-title":"Leukemia"},{"key":"e_1_3_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.19"},{"key":"e_1_3_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0116-0"},{"key":"e_1_3_2_1_29_1","first-page":"195","volume":"201","author":"Acharya U.H.","unstructured":"Acharya , U.H. , , Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol , 201 9. 12(3): p. 195 - 205 . Acharya, U.H., , Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol, 2019. 12(3): p. 195-205.","journal-title":"Expert Rev Hematol"}],"event":{"name":"ICBBE '20: 2020 7th International Conference on Biomedical and Bioinformatics Engineering","acronym":"ICBBE '20","location":"Kyoto Japan"},"container-title":["2020 7th International Conference on Biomedical and Bioinformatics Engineering"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3444884.3444919","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3444884.3444919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T21:28:13Z","timestamp":1750195693000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3444884.3444919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":29,"alternative-id":["10.1145\/3444884.3444919","10.1145\/3444884"],"URL":"https:\/\/doi.org\/10.1145\/3444884.3444919","relation":{},"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"2021-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}